In addition to the general characteristics, we also reported some novel findings on the incidences of KRAS mutation subgroups and passenger gene mutations, as well as KRAS/TP53 and KRAS/STKII co-mutations, which were reported to be associated with an adverse prognosis of NSCLC [11,12,13,14]. Here, KRAS is linked to non-small cell lung carcinoma.